- \n
- Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt<\/i><\/li>\n
- Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations<\/i><\/li>\n
- Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study<\/i><\/li>\n
- Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts<\/i><\/li>\n
- Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies<\/i><\/li>\n<\/ul>\n
CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nVyome Holdings, Inc., (\u201cVyome\u201d) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq.<\/p>\n\nThis quarter marks Vyome\u2019s first annual reporting period as a listed Nasdaq company. Vyome is a clinical-stage company positioned to accelerate development across immuno-inflammatory and potential orphan indications.<\/p>\n
\n\u201cVyome is targeting one of the biggest challenges in the world today – inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it\u2019s our capital structure or the development of our assets,\u201d said Krishna Gupta, Chairman of Vyome. \u201cWe had a great first fiscal year completion as a public company, thanks to our unique strengths, including expertise in\/access to the US-India innovation corridor.\u201d<\/p>\n
\n\u201cThis annual reporting marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in 2025 as a public company and strengthening our organization while advancing our lead program,\u201d noted Venkat Nelabhotla, CEO of Vyome. \u201cThe promising final Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients.\u201d<\/p>\n
VT-1953: Highly Encouraging Final Phase 2 Study Readouts<\/b><\/p>\n
\nThe Company\u2019s lead clinical program, VT-1953, a novel, potential first-in-class topical product targeting symptoms of putrid smell and pain in malignant fungating wounds (\u201cMFW\u201d), which is an inflammatory condition afflicting an estimated one million cancer patients, continued to show strong clinical momentum.<\/p>\n
- \n
- \nFinal Phase 2 Investigator-Initiated Study data demonstrated a statistically significant reduction in the study\u2019s primary endpoint, malodor (P<0.002)<\/p>\n<\/li>\n
- \nPatients also reported significant reductions in pain and improvements in quality of life<\/p>\n<\/li>\n
- \nVT-1953 continues to show an excellent safety profile<\/p>\n<\/li>\n<\/ul>\n
Strong Progress on Milestones of VT-1953<\/b><\/p>\n
- \n
- \nThe Company submitted an Orphan Drug Designation application to the FDA in January 2026<\/p>\n<\/li>\n
- \nFDA interactions on pivotal study design and orphan drug designation are expected in the second quarter of 2026<\/p>\n<\/li>\n
- \nPer an independent valuation analysis commissioned by Vyome and conducted by Destum Partners, Inc., treatment of malodor of MFW represents a potential addressable pharmacologic market opportunity of $2.2B in the U.S., with no FDA-approved drug; VT-1953 would be the only FDA approved solution on the market, with a potential valuation of $1B after a successful completion of a Phase 3 study<\/p>\n<\/li>\n<\/ul>\n
\nMFW is a devastating, rare condition affecting 5\u201314% of advanced cancer patients, often leading to severe emotional and social burden due to an extremely bad smell, which prevents any interaction with family or friends.<\/p>\n
\nThe Company previously reported strong preclinical efficacy for VT-1908 eye drops in uveitis models in the third quarter of 2025, reinforcing its promise as a highly needed steroid-sparing candidate in treating uveitis.<\/p>\n
2025 Financial Summary<\/b><\/p>\n
Cash Position<\/b><\/p>\n
- \n
- \nTotal cash, cash equivalents, and short-term investments are approximately $4.94 million as of December 31, 2025, together with an additional financing of approximately $5.3 million in January 2026 from our ATM agreement, which is expected to cover our anticipated runway, including potential VT-1953 pivotal study interim analysis around mid-2027.<\/p>\n<\/li>\n<\/ul>\n
Operating Summary<\/b><\/p>\n
- \n
- \nR&D of $588,258 and G&A expenses of $2,365,565 reflect pre- and post-merger activities.<\/p>\n<\/li>\n
- \nNet loss of $10,477,713 primarily reflects one-time merger and financing-related expenses of approximately $7.7 million, including non-cash charges associated with these transactions.<\/p>\n<\/li>\n<\/ul>\n
Clean Capital Structure<\/b><\/p>\n
- \n
- \n5,919,337 outstanding shares of common stock<\/p>\n<\/li>\n
- \nNo preferred stock or debt<\/p>\n<\/li>\n<\/ul>\n
Company to Hold Conference Call to Review Results<\/b><\/p>\n
\nThe Company will host a conference call and webcast on Monday, March 30, 2026, at 11:00 a.m. ET to discuss the results. To access the webcast, please use the following link https:\/\/event.choruscall.com\/mediaframe\/webcast.html?webcastid=802ocw0n<\/a> or dial in at 1-877-317-6789 (U.S.\/Canada toll-free) \/ +1-412-317-6789 (international).<\/p>\n
\nA replay will be available on the Company Website.<\/p>\n
About Vyome Holdings, Inc.:<\/b><\/p>\n
\nVyome is building the world\u2019s premier platform spanning the US-India innovation corridor. Vyome\u2019s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.<\/p>\n
\n
\n \u00a0<\/td>\n<\/tr>\n \n SUMMARY FINANCIAL STATEMENTS<\/b><\/td>\n<\/tr>\n \n SUMMARY OF CONSOLIDATED BALANCE SHEETS AS OF<\/i>,<\/td>\n<\/tr>\n \n <\/tr>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n December 31, 2025<\/b><\/p>\n<\/td>\n
\n \n December 31, 2024<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nCash and cash equivalents<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n4,982,333<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n101,904<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nOther current assets<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n455,988<\/p>\n<\/td>\n
\n \n \n \n200,142<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nLong term assets<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,058,856<\/p>\n<\/td>\n
\n \n \n \n1,079,515<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal assets<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n6,497,177<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,381,561<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nLiabilities<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n2,735,160<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n5,772,594<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal Stockholders\u2019 equity (deficit)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,762,017<\/p>\n<\/td>\n
\n \n \n \n(4,391,033<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal liabilities and stockholders\u2019 equity<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n6,497,177<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,381,561<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n SUMMARY OF CONSOLIDATED STATEMENTS OF OPERATIONS<\/i><\/td>\n<\/tr>\n \n <\/tr>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n Year ended
\n
December 31, 2025<\/b><\/p>\n<\/td>\n\n \n Year ended
\n
December 31, 2024<\/b><\/p>\n\n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nRevenues<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n319,714<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n256,944<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nCost of goods sold<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(100,943<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(61,974<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nGross profit<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n218,771<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n194,970<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nOperating expenses<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,965,808<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,201,310<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTransactional and financial advisory fees including non-cash expenses<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n7,705,533<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nOperating loss<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(10,452,570<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(1,006,340<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nInterest and other expenses, net<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(25,143<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(441,121<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nNet loss<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(10,477,713<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(1,447,461<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260326931929\/en\/<\/a><\/span><\/p>\n
\nMedia:\u2028
\n
contact@vyometx.com<\/a><\/p>\n\nVisit us on social media:
\n
Facebook
\n<\/a>
X
\n<\/a>
LinkedIn<\/a><\/p>\nKEYWORDS:<\/b> Massachusetts United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Other Health Health Pharmaceutical Clinical Trials Oncology<\/p>\n
- \nTotal cash, cash equivalents, and short-term investments are approximately $4.94 million as of December 31, 2025, together with an additional financing of approximately $5.3 million in January 2026 from our ATM agreement, which is expected to cover our anticipated runway, including potential VT-1953 pivotal study interim analysis around mid-2027.<\/p>\n<\/li>\n<\/ul>\n
- Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260326931929\/en\/2758092\/3\/Vyome_New_Logo_2025.jpg\"){kind=logo}
<\/td>\n<\/tr>\n